Exhibit 99.1 Net Loss: Excluding costs associated with being a public company listed on the NASDAQ Capital Market amounting to US$188,341, the Company recorded a reduced net loss of US$1.66 million for the financial year ended December 31, 2024. Including these costs, the audited net loss was US$1.85 million, representing a 39% improvement compared to the net loss of US$3.03 million in 2023. The reduction was primarily due to the absence of initial public offerings ("IPO") related expenses, as well as lower ...

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial re ...

SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board of Directors (the "Board") as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year of the Snake. ...

SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board of Directors (the “Board”) as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year of the Snake. ...

In another separate development, the Company is pleased to announce that the Intellectual Property Corporation of Malaysia has granted a patent for its licenced iPSC-derived hybrid γδ NKT cells technology, which targets solid and haematological cancers. "This acquisition is to unlock the therapeutic potential of umbilical cord blood and adds strategic capital to our vision to develop cytotoxic γδ T cells for cancer treatment" said Peter Choo, Chairman of CytoMed "We aim to be the pre-eminent player in the γ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has obtained board approval to launch, subject to certain terms and conditions, a pilot program ("Program") to isolate and cryo-store peripheral blood mononuclear cell ...

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement ("RCA") with Sengkang General Hospital Pte Ltd ("SKH"), a public hospital in Singapore and a membe ...

Financial Performance - As of December 31, 2022, the company reported accumulated losses of S$8.20 million, with net cash used in operating activities amounting to S$1.40 million[631]. - The company had cash and cash equivalents of S$1.58 million as of December 31, 2022, down from S$2.51 million in 2021[632]. - Net cash used in investing activities for 2022 was S$473,305, primarily due to the purchase of property, plant, and equipment[638]. - The company generated S$968,716 from financing activities in 2022, mainly from the issuance of ordinary shares totaling S$1.22 million[641]. Future Outlook - The company expects significant increases in expenses and capital requirements as it continues R&D activities and seeks regulatory approvals for product candidates[631]. - The company plans to fund its operations through various sources, including loans, equity, and debt financings[632]. - The company has contractual obligations totaling S$2.16 million, with S$1.83 million related to convertible bonds due within one year[647]. - The company has not yet commercialized any product candidates and does not expect to generate revenue from commercial sales in the foreseeable future[630]. Research and Development - The company is conducting the ANGELICA Trial with National University Hospital Singapore as part of its ongoing R&D efforts[642]. - The company estimates accrued R&D expenses based on known facts and circumstances, with no material adjustments to prior estimates reported to date[653]. Company Classification - The company is classified as an "emerging growth company" and has opted for delayed adoption of certain accounting standards[659]. - The company will maintain its emerging growth status until it exceeds U.S.$1.235 billion in annual revenue or meets other specified criteria[660]. Shareholder Actions - On April 21, 2023, the mDR Convertible Loan was converted into 589,509 ordinary shares at approximately U.S.$1.89774 per share[661].